

Table S4. Lipid and lipoprotein levels in noncarriers and heterozygotes for synonymous(S) and nonsynonymous(NS) variants in the Copenhagen City Heart Study (left, top and bottom) and the Copenhagen General Population Study (right, bottom).

	CCHS				CGPS			
	Noncarriers	Heterozygotes for S	Heterozygotes for all NS	Heterozygotes for NS without A164S	Noncarriers	Heterozygotes for S	Heterozygotes for all NS	Heterozygotes for NS without A164S
Variants typed in CCHS: A(-22)A, V(-20)A, P4R, V11X, K12K, S25S, G35V, S36A, A37T, F71Y, N74K, E76Q, K107del, S142R, L144R, R151H, A152T, R153C, A164S, A164A, S167L, A190A, H199H, P220P								
No. of individuals	10,251	18	61	38				
Age (years)	59 (45-69)	65 (47-68)	59 (44-68)	61 (43-71)				
Sex (M/F)	4,540/5,711	9/9	28/33	15/23				
Apolipoprotein A-I (mg/dL)	140 (123-161)	129 (103-149)	137 (115-161)	130 (107-162)				
HDL cholesterol (mmol/L)	1.5 (1.2-1.8)	1.3 (0.9-1.7)	1.4 (1.1-1.7) ^a	1.3 (1.0-1.7) ^a				
Total cholesterol (mmol/L)	6.0 (5.1-6.9)	5.8 (5.3-6.1)	6.0 (5.4-6.7)	6.0 (5.7-6.7)				
LDL cholesterol (mmol/L)	3.6 (2.9-4.4)	3.5 (3.0-3.7)	3.7 (3.1-4.3)	3.8 (3.3-4.4)				
Triglycerides (mmol/L)	1.5 (1.1-2.2)	1.6 (1.2-2.4)	1.8 (1.3-2.4)	1.8 (1.5-2.4) ^a				
Lipid lowering therapy (%)	1	0	2	0				
Variants typed in CCHS and CGPS: K12K, S25S, S36A, F71Y, K107del, L144R, A164S, A190A								
No. of individuals	10,272	12	46	22	44,977	56	206	98
Age (years)	59 (45-69)	65 (49-67)	60 (44-67)	63 (43-68)	57 (47-67)	58 (47-68)	57 (48-66)	56 (46-68)
Sex (M/F)	4,549/5,723	7/5	21/25	7/15	20,210/24,767	29/27	86/120	31/67 ^b
Apolipoprotein A-I (mg/dL)	140 (123-161)	129 (103-143)	137 (117-154)	126 (106-162)	156 (139-176)	145 (130-173) ^a	151 (134-168) ^b	141 (129-162) ^b
HDL cholesterol (mmol/L)	1.5 (1.2-1.8)	1.3 (1.0-1.6)	1.4 (1.1-1.7)	1.2 (1.0-1.6) ^b	1.6 (1.3-2.0)	1.5 (1.2-1.8)	1.5 (1.2-1.8) ^b	1.3 (1.0-1.6) ^b
Total cholesterol (mmol/L)	6.0 (5.1-6.9)	5.8 (5.4-6.0)	6.2 (5.0-6.9)	6.2 (5.0-6.9)	5.6 (4.9-6.3)	5.4 (4.7-6.2)	5.5 (4.8-6.1)	5.5 (4.7-6.1)
LDL cholesterol (mmol/L)	3.6 (2.9-4.4)	3.5 (3.0-3.7)	3.7 (2.9-4.5)	3.7 (3.1-4.5)	3.2 (2.6-3.8)	3.0 (2.6-3.9)	3.2 (2.6-3.8)	3.3 (2.7-3.8)
Triglycerides (mmol/L)	1.5 (1.1-2.2)	1.5 (1.2-2.2)	1.8 (1.2-2.2)	1.8 (1.5-2.4)	1.4 (1.0-2.1)	1.5 (1.0-2.3)	1.4 (0.9-2.1)	1.5 (0.9-2.4)
Lipid lowering therapy (%)	1	0	1	2	10	9	12	12

Values are median (interquartile range) or percentage for noncarriers and heterozygotes for S and NS variants. Kruskal-Wallis test with Mann-Whitney U as a post hoc test or Fishers exact test was used for continuous and categorical traits, respectively. LDL cholesterol levels were calculated using the Friedewald equation if triglycerides were ≤ 4 mmol/L, but measured directly at higher triglyceride levels. Lipid-lowering therapy was self-reported. ^aP<0.05 and ^bP<0.01 for heterozygotes versus noncarriers.